Last reviewed · How we verify
Ferring Pharmaceuticals — Portfolio Competitive Intelligence Brief
Private (Private)
5 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Menopur | MENOTROPINS | marketed | Other | 2013-01-01 | ||
| Firmagon | degarelix | marketed | Gonadotropin Releasing Hormone Receptor Antagonist | Gonadotropin-releasing hormone receptor | Oncology | 2008-01-01 |
| Acthrel | corticorelin ovine | marketed | Nephrology | 1996-01-01 | ||
| Endometrin | progesterone | marketed | Progesterone [EPC] | Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1 | Women's Health | |
| Choriogonadotropin | chorionic gonadotrophin | marketed | Metabolic |
Therapeutic area mix
- Metabolic · 1
- Nephrology · 1
- Oncology · 1
- Other · 1
- Women's Health · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Endometrin · 10548904 · Method of Use · US
- — Endometrin · 10537584 · Formulation · US
- — Endometrin · 8580293 · Method of Use · US
Competitive overlap (companies sharing drug classes)
- · 1 shared drug class
- AbbVie · 1 shared drug class
- Dunamenti REK Istenhegyi IVF Center · 1 shared drug class
- Merck KGaA · 1 shared drug class
- Organon Usa Organon · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Ferring Pharmaceuticals:
- Ferring Pharmaceuticals pipeline updates — RSS
- Ferring Pharmaceuticals pipeline updates — Atom
- Ferring Pharmaceuticals pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Ferring Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ferring. Accessed 2026-05-13.